New hope for tough seizures: Long-Term safety trial launches

NCT ID NCT07219407

Recruiting now Disease control Sponsor: Rapport Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the long-term safety of an experimental drug called RAP-219 in 30 adults whose focal seizures do not respond well to current treatments. Participants must have already completed a related earlier study. The goal is to see if RAP-219 remains safe and helps reduce seizure frequency over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY FOCAL EPILEPSY FOCAL ONSET SEIZURE FOCAL SEIZURE REFRACTORY FOCAL EPILEPSY SEIZURE

Contacts and locations

Locations

Baylor College of Medicine
RECRUITING

Houston, Texas, 770300, United States
Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44195, United States
Consultants in Epilepsy and Neurology, PLLC
RECRUITING

Boise, Idaho, 83702, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
NYU Langone Comprehensive Epilepsy Center
RECRUITING

New York, New York, 10016, United States
University of Pennsylvania - Department of Neurology
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.